Newsletter Signup | Join Community
Dr. Ruben Mesa, Mays Cancer Center answers questions about the management of polycythemia vera and myelofibrosis.
Connect with others and learn about lymphoma, leukemia, hodgkin's disease and myeloproliferative neoplasms.
Inrebic represents a new treatment option for Jakafi-resistant Myelofibrosis
Idasanutlin is active in the treatment of PV and ET and is currently being evaluated in a global phase 2 trial.
Jakafi associated anemia and low platelet counts can be improved with addition of thalidomide, stanozolol and prednisone
Research suggests conflicting results with Interferon treatment of polycythemia vera and essential thrombocythemia.
Understand the symptoms, diagnosis, treatment & management of Polycythemia Vera.
Is it worth going to someone who specializes in the treatment of MPNs like PV MF or ET?
MF - ELZONRISTM (tagraxofusp; SL-401) trials in MF look promising: https://ir.stemline…
Read the news update about the risk of lymphoma with treatment; has anyone's doctor discussed this…